DCV Technologies
HCID Member | Biotech Specialty Pharma
DCV Technologies, Inc.
Little Rock, AK 72205-7199 USA
phone: 501-686-6696
fax:
Symbol Private
Exchange Private
Founded 2003
Employees 4
www.dcvtech.net
Research Sector Biotech Specialty Pharma
Summary Description
Development of therapeutic vaccines for the treatment of cancer.
Management
CEO-Martin Cannon, Ph.D.
Keywords
therapeutic vaccines, cancer, dendritic cell vaccines, DC vaccines, gynecological malignancy vaccine, prostate cancer vaccine, antigens,

Comment | Printable Version | Nov. 20, 2008
If you work for DCV Technologies and want to update this profile, click here

Description
DCV Technologies, Inc. is dedicated to the development of therapeutic vaccines for the treatment of cancer, based on core technologies developed at the University of Arkansas for Medical Sciences (UAMS).
Products / Services
Antigens licensed by DCV and the diseases in which they are expressed:
  • TADG-14-Ovary, Cervix, Breast, Colon
  • TADG-14 Variant-Ovary, Cervix, Breast, Colon
  • TADG 15-Ovary, Prostate, Breast, Lung
  • TADG 12-Ovary, Breast
  • TADG 12 Variant D-Ovary, Breast
  • TADG 12 Variant V-Ovary, Breast
  • Hepsin-Ovary, Prostate, Lung
  • Hepsin Variant-Ovary, Prostate, Lung
  • SCCE-Ovary, Pancreatic, Colon
  • ALP-Ovary, Lung
  • MMP7-Ovary, Prostate, Colon , Lung
  • TADG7-Ovary
  • CA125-Ovary
Technology / Differentiation
  • Exclusively licensed rights to 14 known tumor antigens expressed by cancers of the reproductive tract and breast cancer.
  • Patent portfolio includes 14 domestic patents, 6 foreign patents, and 31 pending filings.
  • License includes the first rights to license new technology in the field of cancer vaccines from UAMS.
  • Sound process for producing dendritic cell-based vaccines has been developed.
  • Vaccines show high selectivity for attacking targeted diseases. Our vaccines exhibit low toxicity, minimal side-effects and higher quality of life
Market / Customers
In the United States:
  • Approximately 25,000 new cases of ovarian cancer are diagnosed annually.
  • 40,880 new cases of endometrial cancer were projected to occur in 2005.
  • It is estimated that, the market for cancer vaccines will increase substantially from to nearly $1.3 billion in 2008./
Competitors / Substitutes / Alternatives
Cancer vaccines are currently offered for only a limited number of cancers that affect people worldwide.

The approved vaccines have offered additional choices to victims of cancer and have shown favorable results in a significant number of treated patients.
The cancers with currently approved and marketed vaccines include bladder, colorectal, and melanoma.

Dendrion is currently completing clinical trials in prostrate cancer with encouraging early results.
Strategy
DCV Technologies, Inc. is focused on leveraging proprietary technologies and developing key collaborative agreements to advance the development and clinical testing of therapeutic vaccines.
Funding
A Small Business Technology Transfer grant from the National Cancer Institute and sponsorship from the Arkansas Science and Technology Authority has supported preclinical testing of a second generation, enhanced DC vaccine for ovarian cancer.

DCV is actively seeking funding to further its preclinical research program and to advance its therapeutic vaccine products through Phase I and Phase II clinical trials.
Status
DCV's technology has successfully completed a Phase I trial for cervical cancer.

Preclinical work for vaccines for prostate and ovarian cancers and are seeking FDA approval for Phase I trials of these dendritic vaccines.